相关实验视频
Updated: Feb 28, 2026
05:50
Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles
Published on: June 2, 2023
1.9K
在PLGA微球中调节现有的梅洛西卡姆形式,以实现药物持续释放和有效的骨关节炎治疗
Haonan Wu1, Fan Wang1, Yameng Qu1
1Key Laboratory of Pharmaceutical Quality Control of Hebei Province, School of Pharmaceutical Sciences, Hebei University, Baoding 071000, China; College of Traditional Chinese Medicine, Hebei University, Baoding 071000, China.
International journal of pharmaceutics
|February 26, 2026
概括
这种药物是药物,是药物.
科学领域:
- 生物材料科学 生物材料科学
- 药物运输 药物运输 药物运输
- 药理学 药理学是指药理学的学科.
背景情况:
- 聚 (乳糖-糖酸) (PLGA) 微球对于控制药物输送至关重要.
- 药物在PLGA微球中的物理状态显著影响其性能.
- 骨关节炎 (OA) 需要有效的关节内 (IA) 治疗关节炎.
研究的目的:
- 为了配制含有梅洛西卡姆的PLGA微球 (MLX-MS),用于持续的关节内释放.
- 调查药物的现有状态 (微晶,粒子,分子) 如何影响MLX-MS特征.
- 在OA子模型中评估不同MLX-MS配方的治疗疗效.
主要方法:
- 使用共溶剂或微化技术制备了微球,改变了梅洛西卡姆的状态.
- 描述包括SEM-EDS,XRD和体外释放研究.
- 在体内有效性通过IA注射在OA子中进行评估,包括降解和药理动力学.
主要成果:
- 药物的现有状态与关节腔中的MLX-MS释放和降解动力学直接相关.
- 在分子状态下 (Mol-MS) 含有 meloxicam 的微球显示出最佳的持续释放.
- 在OA子中,Mol-MS为关节炎提供了更有效的治疗结果.
结论:
- 药物的物理状态是设计可注射PLGA微球以控制释放的关键因素.
- 在PLGA微球内以分子状态配制梅洛西卡姆,优化了OA的持续释放和治疗疗效.
- 这项研究为开发用于关节疾病的先进IA药物输送系统提供了宝贵的见解.
相关概念视频
01:11Oral Drug Delivery Systems: Delayed-Release Systems
69
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
69
01:26Oral Drug Delivery Systems: Continuous-Release Systems
77
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
77
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
53
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
53
01:23Modified-Release Drug Delivery Systems: Classification
93
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
93
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
50
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
50
01:19Modified-Release Drug Delivery Systems: Overview
65
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
65